GPRC6A

Across TCGA pan-cancer cohorts, GPRC6A RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated GPRC6A data layer compared with 10 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GPRC6A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPRC6A expression acts as an unfavorable survival marker, although some lineages such as UVM and SCLC show a favorable association.

STAD, THCA, and ACC are the cancer types where GPRC6A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.311	0.475	<.001	86	view →
THCA	DFS	Tertile	All	0.697	0.887	<.001	78	view →
ACC	DFS	Median	All	0.331	0.754	<.001	53	view →
UVM	DFS	Median	All	0.916	0.575	.003	52	view →
LIHC	OS	Tertile	All	0.550	0.725	<.001	45	view →
DLBC	OS	Tertile	III,IV	0.154	0.735	.010	40	view →
SCLC	DFS	Tertile	All	0.682	0.418	.021	38	view →
CHOL	OS	Tertile	All	0.240	0.700	.007	36	view →
LUAD	DFS	Quartile	IV	0.466	0.819	.004	30	view →
PRAD	DFS	Tertile	All	0.906	0.727	<.001	18	view →
READ	OS	Median	IV	0.913	0.513	.005	13	view →
MESO	OS	Tertile	III,IV	0.265	0.417	.047	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

GPRC6A–STAD (DFS)

Open the STAD breakdown →